Indication: Neuroblastoma

A Pilot Study of Dinutuximab in Combination with Irinotecan and Temozolomide in the PostConsolidation Setting for High-Risk Neuroblastoma

Sub-indication: Neuroblastoma

Study Type: Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Sponsor: COG

Learn more at ClinicalTrials.gov

Email for more information: NCRI-Cancer@NortonHealthcare.org

Search our entire site.